Login to Your Account

Nektar drug glows dimly in late-stage breast cancer trial, BEACON

By Michael Fitzhugh
Staff Writer

Wednesday, March 18, 2015

Women with advanced breast cancer given the Nektar Therapeutics Inc. drug NKTR-102 (etirinotecan pegol) after earlier cancer treatments lived just 2.1 months longer than those treated with a chemotherapy chosen by their doctors, missing the phase III study's primary endpoint. While subsets of patients fared better, the study failed to achieve statistical significance on primary and secondary endpoints.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription